FDA Policy Changes Spark Intense Debate Over Rare Disease Drug Approval Standards
The regulatory landscape for orphan drugs is undergoing a profound transformation as the Food and Drug Administration grapples with the complexities of
by 
Josh Weiner
Josh Weiner